2041 related articles for article (PubMed ID: 16630937)
21. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
22. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
23. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial.
Wessel F; Chartier A; Meunier JP; Magnan A
Clin Drug Investig; 2012 Jul; 32(7):451-63. PubMed ID: 22594491
[TBL] [Abstract][Full Text] [Related]
26. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
[TBL] [Abstract][Full Text] [Related]
27. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
[TBL] [Abstract][Full Text] [Related]
28. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis.
Bowen T; Greenbaum J; Charbonneau Y; Hebert J; Filderman R; Sussman G; Del Carpio J; Gold M; Keith P; Moote W; Cecchetto S; Cecchetto O; Sharp D; Broutin O; André C
Ann Allergy Asthma Immunol; 2004 Nov; 93(5):425-30. PubMed ID: 15562880
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
31. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis.
Valovirta E; Berstad AK; de Blic J; Bufe A; Eng P; Halken S; Ojeda P; Roberts G; Tommerup L; Varga EM; Winnergard I;
Clin Ther; 2011 Oct; 33(10):1537-46. PubMed ID: 21999887
[TBL] [Abstract][Full Text] [Related]
32. Specific immunotherapy with high dose SO standardized grass allergen tablets was safe and well tolerated.
Calderón M; Essendrop M
J Investig Allergol Clin Immunol; 2006; 16(6):338-44. PubMed ID: 17153880
[TBL] [Abstract][Full Text] [Related]
33. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
34. Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy.
Calderon MA; Birk AO; Andersen JS; Durham SR
Allergy; 2007 Aug; 62(8):958-61. PubMed ID: 17620076
[TBL] [Abstract][Full Text] [Related]
35. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.
Durham SR; Emminger W; Kapp A; Colombo G; de Monchy JG; Rak S; Scadding GK; Andersen JS; Riis B; Dahl R
J Allergy Clin Immunol; 2010 Jan; 125(1):131-8.e1-7. PubMed ID: 20109743
[TBL] [Abstract][Full Text] [Related]
36. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care.
Röder E; Berger MY; Hop WC; Bernsen RM; de Groot H; Gerth van Wijk R
J Allergy Clin Immunol; 2007 Apr; 119(4):892-8. PubMed ID: 17321581
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial.
Maloney J; Bernstein DI; Nelson H; Creticos P; Hébert J; Noonan M; Skoner D; Zhou Y; Kaur A; Nolte H
Ann Allergy Asthma Immunol; 2014 Feb; 112(2):146-153.e2. PubMed ID: 24468255
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe.
Canonica GW; Poulsen PB; Vestenbaek U
Respir Med; 2007 Sep; 101(9):1885-94. PubMed ID: 17611095
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
Rossi RE; Monasterolo G; Coco G; Silvestro L; Operti D
Vaccine; 2007 Jan; 25(5):957-64. PubMed ID: 17045368
[TBL] [Abstract][Full Text] [Related]
40. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
